ES2176342T3 - Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico. - Google Patents

Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.

Info

Publication number
ES2176342T3
ES2176342T3 ES95936537T ES95936537T ES2176342T3 ES 2176342 T3 ES2176342 T3 ES 2176342T3 ES 95936537 T ES95936537 T ES 95936537T ES 95936537 T ES95936537 T ES 95936537T ES 2176342 T3 ES2176342 T3 ES 2176342T3
Authority
ES
Spain
Prior art keywords
type
sequences
hcv
new
subtipos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936537T
Other languages
English (en)
Other versions
ES2176342T5 (es
Inventor
Geert Maertens
Lieven Stuyver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176342(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of ES2176342T3 publication Critical patent/ES2176342T3/es
Application granted granted Critical
Publication of ES2176342T5 publication Critical patent/ES2176342T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DE NUCLEOTIDOS GENOMICOS Y A LAS SECUENCIAS DE AMINOACIDOS CORRESPONDIENTES A LA REGION DE CODIFICACION DE ESTOS GENOMAS. LA INVENCION SE REFIERE A NUEVAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV QUE SON DIFERENTES DE LAS SECUENCIAS DE TIPOS Y SUBTIPOS DE HCV CONOCIDAS. EN PARTICULAR, LA PRESENTE INVENCION SE REFIERE A NUEVAS SECUENCIAS DEL HCV TIPO 7, NUEVAS SECUENCIAS DEL HCV TIPO 9, NUEVAS SECUENCIAS DEL HCV TIPO 10 Y NUEVAS SECUENCIAS DEL HCV TIPO 11. LA PRESENTE INVENCION TAMBIEN SE REFIERE A NUEVAS SECUENCIAS DE LOS SUBTIPOS 1D, 1E, 1F Y 1G DEL HCV TIPO 1; NUEVAS SECUENCIAS DE LOS SUBTIPOS 2E, 2F, 2G, 2H, 2I, 2K Y 2L DEL HCV TIPO 2; NUEVAS SECUENCIAS DEL SUBTIPO 3G DEL HCV TIPO 3; NUEVAS SECUENCIAS DE LOS SUBTIPOS 4K, 4L Y 4M DEL HCV TIPO 4; A UN PROCESO PARA LA PREPARACION DE LAS MISMAS Y A SU USO PARA DIAGNOSTICOS, PROFILAXIS Y TERAPIAS. EN PARTICULAR, EN LA PRESENTE INVENCION SE PRESENTAN NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOSDE LAS REGIONES DEL NUCLEO, LAS REGIONES E1 Y LA NS5 DE NUEVOS HCV TIPO 7, 9, 10 Y 11, ASI COMO NUEVAS VARIANTES (SUBTIPOS) DE LOS HCV TIPO 1, 2, 3 Y 4. ESTAS SECUENCIAS NUEVAS DE HCV SON UTILES PARA DIAGNOSTICAR LA PRESENCIA GENOTIPOS O SEROTIPOS DEL HCV TIPO 1 Y/O TIPO 2 Y/O TIPO 3 Y/O TIPO 4 Y/O TIPO 7 Y/O TIPO 9 Y/O TIPO 10 Y/O TIPO 11 EN UNA MUESTRA BIOLOGICA. ADEMAS, LA DISPONIBILIDAD DE ESTAS NUEVAS SECUENCIAS ESPECIFICAS PARA LOS TIPOS PUEDE AUMENTAR LA SENSIBILIDAD GENERAL DE DETECCION DEL HCV Y DEBERIA DEMOSTRAR TAMBIEN SU UTILIDAD PARA FINES PROFILACTICOS Y TERAPEUTICOS.
ES95936537T 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. Expired - Lifetime ES2176342T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP94870166 1994-10-21
EP95870076 1995-06-28
EP95870076 1995-06-28

Publications (2)

Publication Number Publication Date
ES2176342T3 true ES2176342T3 (es) 2002-12-01
ES2176342T5 ES2176342T5 (es) 2010-02-09

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95936537T Expired - Lifetime ES2176342T5 (es) 1994-10-21 1995-10-23 Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.

Country Status (12)

Country Link
US (2) US7129337B1 (es)
EP (2) EP1076092A3 (es)
JP (2) JPH10507643A (es)
AT (1) ATE218617T1 (es)
AU (1) AU702436B2 (es)
BR (1) BR9509421A (es)
CA (1) CA2201703A1 (es)
DE (1) DE69526973T3 (es)
DK (1) DK0804584T3 (es)
ES (1) ES2176342T5 (es)
PT (1) PT804584E (es)
WO (1) WO1996013590A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
CZ298268B6 (cs) 1998-04-17 2007-08-08 Innogenetics N. V. Imunodiagnostický test používající redukující cinidla
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
IL140217A0 (en) * 1998-06-24 2002-02-10 Innogenetics Nv Particles of hcv envelope proteins: use for vaccination
AU9215101A (en) * 2000-08-17 2002-02-25 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
CA2552949C (en) * 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
RU2267496C2 (ru) 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
KR20150098683A (ko) 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
LT2468770T (lt) 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
AU2007288129B2 (en) * 2006-08-25 2013-03-07 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant HCV E2 glycoprotein
EP2121991A2 (en) 2006-10-20 2009-11-25 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
JP5292300B2 (ja) 2006-11-24 2013-09-18 エーシー イミューン ソシエテ アノニム 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのn−(メチル)−1h−ピラゾール−3−アミン誘導体、n−(メチル)−ピリジン−2−アミン誘導体、およびn−(メチル)−トリゾール−2−アミン誘導体
RU2567151C2 (ru) 2007-06-12 2015-11-10 Ац Иммуне С.А. Гуманизированные антитела к амилоиду бета
CL2008001742A1 (es) 2007-06-12 2008-11-21 Ac Immune Sa Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
US20100227314A1 (en) * 2007-08-09 2010-09-09 Dmitry Alexandrovich Gryadunov Method of identification of genotype and subtype of hepatitis c virus on a biological microchip
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP5911470B2 (ja) 2010-04-16 2016-04-27 エーシー・イミューン・エス・アー アミロイドまたはアミロイド様タンパク質と関連する疾患を治療するための新規化合物
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Phosphonus recognition antibodies
CN103189050B (zh) 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体
CA2850686C (en) 2011-10-07 2020-09-08 Ac Immune S.A. Phosphospecific antibodies recognising tau
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
ES2728864T3 (es) 2012-08-31 2019-10-29 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
US9891225B2 (en) * 2013-05-10 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of HCV antigen/antibody
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3978526A1 (en) 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
CA2065287C (en) 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
NZ236491A (en) 1989-12-18 1993-10-26 Wellcome Found Post-transfusional non-a non-b hepatitis viral polypeptides, dna, antigenic polypeptides and antibodies to the polypeptides
FI913068A (fi) 1990-06-25 1991-12-26 Univ Osaka Res Found Non-a-, non-b-hepatitisviruspartiklar.
DE69233234T2 (de) 1991-05-08 2004-08-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Genomische hcv-sequenzen für diagnostik und therapie
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
DE69232859T2 (de) 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
ES2065863T3 (es) 1991-11-21 2003-09-01 Common Services Agency Analisis para la deteccion de virus de la hepatitis c.
CA2139100C (en) * 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk C型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにc型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
BR9509421A (pt) 1997-09-30
AU3844095A (en) 1996-05-23
DE69526973T2 (de) 2003-01-02
PT804584E (pt) 2002-11-29
US7129337B1 (en) 2006-10-31
US20020183508A1 (en) 2002-12-05
DE69526973D1 (de) 2002-07-11
DK0804584T3 (da) 2002-09-23
US6974864B2 (en) 2005-12-13
EP1076092A2 (en) 2001-02-14
JPH10507643A (ja) 1998-07-28
WO1996013590A2 (en) 1996-05-09
EP0804584B2 (en) 2008-07-09
EP0804584A1 (en) 1997-11-05
DE69526973T3 (de) 2010-01-07
ES2176342T5 (es) 2010-02-09
WO1996013590A3 (en) 1996-08-15
JP2005118044A (ja) 2005-05-12
EP1076092A3 (en) 2001-03-28
EP0804584B1 (en) 2002-06-05
AU702436B2 (en) 1999-02-18
ATE218617T1 (de) 2002-06-15
CA2201703A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
ES2176342T3 (es) Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.
DE69330372T2 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
Kolykhalov et al. Identification of a highly conserved sequence element at the 3'terminus of hepatitis C virus genome RNA
BR9405334A (pt) Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
Tapay et al. A polymerase chain reaction protocol for the detection of various geographical isolates of white spot virus
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
MC2188A1 (fr) Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
BE2014C049I2 (en) Circovirus sequences associated with piglet weight loss disease (PWD)
Mahony et al. Genetic analysis of bovine viral diarrhoea viruses from Australia
DE69126617T2 (de) Nanbv diagnostik: für die untersuchung auf hepatitis c verwendbare polynukleotide
CN108330210B (zh) 寨卡病毒、登革热病毒和基孔肯雅病毒核酸检测试剂盒及其用途
WO2001002601A3 (en) Cell-based assay systems for examining hcv ns3 protease activity
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
Barros et al. Phylogenetic analysis of Portuguese bovine viral diarrhoea virus
WO2000058524A3 (en) Typing of human enteroviruses
Tellinghuisen et al. Nucleic acid-dependent cross-linking of the nucleocapsid protein of Sindbis virus
Widjojoatmodjo et al. Comparative sequence analysis of classical swine fever virus isolates from the epizootic in The Netherlands in 1997–1998
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
Garin et al. Highly sensitive Taqman® PCR detection of Puumala hantavirus
Fricke et al. A family of closely related bovine viral diarrhea virus recombinants identified in an animal suffering from mucosal disease: new insights into the development of a lethal disease in cattle
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
Giangaspero et al. Genetic variety of bovine viral diarrhea virus 2 strains isolated from sheep
DE60015210T2 (de) Oligonukleotid Primer zur effizienten reversen Transkription von Hepatitis C Virus (HCV) RNS und Verfahren zu deren Verwendung
EP2914618B1 (en) Flavivirus associated with theiler's disease
Grinev et al. Microarray-based assay for the detection of genetic variations of structural genes of West Nile virus